| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Reference and Education > Psychology > Analysis of Human Analogy Thinking and Artificial Intelligence |
|
Advice Pool - Analysis of Human Analogy Thinking and Artificial Intelligence
One interesting aspect to the human mind is that it thinks in analogies. In other words According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product it relates to one set of events with another set of events which are similar in nature ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in in one or more aspects. This is a fascinating way to use one’s mind in that it allows h lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. umans to make decisions in situations that they have never been in before. It allows th here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe m to think of what they might do in any given situation based on the outcomes of a diffe d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro rent situation. Therefore they can use their experiences and observations and memory to ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc adapt themselves to other situations or events. When programming artificial intelligen easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ce and allowing them to program themselves they too will need this tool. This allows us nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically to take for instance a robotic artificially intelligent android inset them in an environ and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ment of which they have never been in before, thus they will size up the situation in us ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi e their preprogrammed memory or data and observations from sensors of previous events an ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a d outcomes in the deciding what to do. In fact the ability to do this for an artificiall dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod intelligent robotic system is paramount. Indeed, it behooves us to look into the best cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin possible method of ensuring that the who, what, when, where, how and why of each event g tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ets categorized correctly in proper data sets and fields and that's when such events occ t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel urring are similar in nature to those already experienced by this individual robot or do ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust n loaded from a collaborative or collective system of experiences is used to better its y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products chances of making the best possible decision in the given event. I feel very strongly ab . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de out the concept of analogy thinking and programming of artificially intelligent robotic elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip systems, so I wanted to bring this up to you. And I hope you will think of this in 2006 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:All That You Need To Know About Refinancing A Loan Seven Things You Should Do To Help You Prepare For Exams
|